中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (10): 727-729.doi: 10.12144/zgmfskin202410727

• 病例报告 • 上一篇    下一篇

糖皮质激素联合度普利尤单抗治疗大疱性类天疱疮合并扁平疣一例

张锐霞,唐俊婷,何盎然   

  1. 昆明医科大学第一附属医院皮肤科，云南昆明，650000
  • 出版日期:2024-10-15 发布日期:2024-08-28

Glucocorticoid combined with dupilumab in the treatment of bullous pemphigoid complicated with verruca plana: a case report

ZHANG Ruixia, TANG Junting, HE Angran   

  1. Department of Dermatology, the First Affiliated Hospital of Kunming Medical University, Kunming 650000, China
  • Online:2024-10-15 Published:2024-08-28

PDF (PC)

63

摘要： 目前大疱性类天疱疮(BP)的治疗主要以糖皮质激素为主，度普利尤单抗是一种治疗BP的新型药物，其疗效已在国内外多篇文献中得到证实。但糖皮质激素联合度普利尤单抗在扁平疣治疗方面的作用暂无相关报道。本文报道一例糖皮质激素联合度普利尤单抗治疗后BP病情控制稳定且泛发性扁平疣消退的病例。查阅国内外相关文献分析，本病例扁平疣短期内消退，可能与度普利尤单抗对免疫功能的调节及皮肤屏障的修复相关。

关键词: 度普利尤单抗, 大疱性类天疱疮, 扁平疣

Abstract: The treatment of bullous pemphigoid (BP) is mainly based on glucocorticoids at present. Dupilumab is a new drug for the treatment of BP, and its efficacy has been confirmed in many literatures at home and abroad. But glucocorticoid combined with dupilumab in treatment of verruca plana was no related reports. We report a case of BP with stable control and regression of generalized verruca plana after the treatment of glucocorticoid combined with dupilumab. The short-term regression of verruca plana in this case may be related to the regulation of immune function and the repair of skin barrier by dupilumab.

Key words: dupilumab, bullous pemphigoid, verruca plana